Obesity Update: CGX-926 Oral Debut, 18% Weight Loss from KAI-9531, Vivani’s Implant Milestone & More
In this week’s Obesity Updates, we spotlight the latest breakthroughs redefining obesity treatment—from AI-driven oral drugs and high-impact GLP-1 data to long-acting implants and global expansion strategies.
🔬 Key Highlights This Week:
🧬 Congruence unveils CGX-926, an oral MC4R-targeting drug for genetic obesity
📈 Hengrui & Kailera’s KAI-9531 shows 18% avg. weight loss in Phase III
💉 Vivani nears data on six-month GLP-1 implant, NPM-115
🌍 Biocon plans global rollout of generic semaglutide by 2027
🧠 Hanmi targets muscle-preserving weight loss with new HOP candidates
🤝 Fangzhou & Novo partner on AI-driven obesity care in China
Whether you’re a researcher, investor, or healthcare strategist, this episode delivers fast, expert-curated insights into the most impactful obesity innovations.
📢 Stay Ahead in Obesity Research!
✅ Like, share, and subscribe for weekly updates
#ObesityResearch #GLP1 #MC4R #CongruenceTherapeutics #VivaniMedical #HanmiPharma #Biocon #NovoNordisk #ClinicalTrials #WeightLossDrugs #HealthcareConsulting #LucidQuest #PharmaNews #BiotechUpdate